VEGFA and Atrophy: These findings correlate well with recent studies showing that eyes treated with anti-VEGF therapy for neovascular AMD are most likely to develop atrophy in areas topographically corresponding to the CNV lesion, and unlikely to develop de-novo geographic atrophy beyond the CNV area13,14,18.